PerkinElmer, Inc.
Feb 3, 2012
PDF

PerkinElmer Highlights New Drug Discovery Research Solutions at the Society for Laboratory Automation and Screening (SLAS) 2012 Conference

SAN DIEGO--()--At the 1st annual Society for Laboratory Automation and Screening Conference in San Diego (Booth #711), PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, will be showcasing several new drug discovery technologies and applications – including innovative products based on the Company’s ALPHA technology and LANCE® Ultra technologies for epigenetics research.

PerkinElmer will be launching the first commercially available, innovative high-throughput cellular assays that allow for the direct measurement of endogenous epigenetic mark modulation, for more relevant results. These assays are extremely simple and automatable, to enable drug target validation and lead compound characterization, replacing more labor intensive technologies such as Western Blot and ELISA. In addition, the expanded epigenetic biochemical enzymatic assays and detection reagents are specifically validated for drug discovery research, for disease states including oncology and neurodegenerative disorders.

“Effective and efficient targeted drug discovery are becoming increasingly critical in the growing field of epigenetics, and we are committed to continuously innovating solutions in support of this research,” said Kevin Hrusovsky, president, Life Sciences and Technology, PerkinElmer. "With these new products, we are delivering to researchers the validated reagents and assays they need to ultimately help advance personalized medicine innovations.”

PerkinElmer’s assay and reagent expansions on display at SLAS include:

  • AlphaLISA cellular detection kits for H3K9 and H3K27
  • AlphaLISA and LANCE Ultra In Vitro Toolbox that now covers over 30 validated enzymatic assays for readers and writers of the histone code

PerkinElmer will also showcase existing products including:

PerkinElmer’s Pre-Show Interactive Workshop:

Building the in vitro to in vivo continuum through novel, disruptive technologies
Sunday, February 5, 9 a.m. – 1 p.m., Room 10, upper level, San Diego Convention Center

With a growing emphasis on translational medicine, it is more important than ever to be able to examine the molecular mechanisms of disease and translate in vitro models into in vivo results, ultimately in humans. Join colleagues as they explore several state-of-the-art, disruptive technologies that enable simpler, faster results in the research and development of new therapies including first in class cell-based epigenetics assays, advanced HTS sequencing sample preparation and data-rich 3D imaging solutions.

Presentations include:

Exploring the scientific and fiscal boundaries of biosample resources
9:15 – 10:00 a.m. – Andy Brooks, PhD Rutgers University Cell and DNA Repository

Novel high throughput in vitro and cellular assays to accelerate drug discovery in epigenetic research
10:00 – 10:45 a.m. – Bo Heinemann, Ph.D, Epitherapeutics ApS Copenhagen

Better in vitro biology: 3D microtissues for drug de-risking
11:00 – 11:45 a.m. – Dr. Ing. Jan Lichtenberg, InSphero AG, Zurich

Together we can revolutionize medicine
11:45 – 12:15 p.m. – Kevin Hrusovsky, President, Life Sciences & Technology, PerkinElmer

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $1.7 billion in 2010, has about 7,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

Contacts

PerkinElmer, Inc.
Mario Fante, 781-663-5602
Corporate Public Relations Manager
mario.fante@perkinelmer.com
or
Edelman (on behalf of PerkinElmer, Inc.)
Amanda L. Connolly, 404-832-6785
amanda.connolly@edelman.com